Varenicline Tartrate
Tardive Dyskinesia
Corporal Michael J. Crescenz VA Medical CenterPhase 4 / ApprovedActive
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 47/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Tardive Dyskinesia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
MT-5199 Neurocrine Biosciences | Phase 4 | BBB |
Ginkgo Biloba Beijing HuiLongGuan Hospital | Phase 3 | BB |
Vitamin B6 Beersheva Mental Health Center | Phase 3 | B |
Safinamide Zambon SpA | Phase 3 | B |
1H-INDOLE-1-CARBOXYLIC ACID, OCTAHYDRO-4-HYDROXY-4-((3-METHYLPHENYL)ETHYNYL)-, METHYL ESTER, (3AR,4S,7AR)- Novartis Pharmaceuticals | Phase 2 | B |
View all 14 →
Same molecule, other indications
Varenicline Tartrate is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →